The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for ...

The U.S. Preventive Services Task Force recommends a low-dose CT scan of the chest for anyone who is between ages 50 and 80 ...

Doctors at Chesapeake Regional Healthcare are able to minimize the pain lung cancer patients undergo with a one-and-done ...

GSK’s GSK’227 has gained Priority Medicines (PRIME) designation from the EMA for the treatment of relapsed ES-SCLC.

In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall ...

Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

China's homegrown medicines are expected to play a more important role in tumor treatment as domestic researchers and ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage ...

An NIH modeling study examined the individual and combined effects of cancer prevention, screening, and treatment. A study ...

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...